Douglas C. Wolf

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.1K citations

Inflammation, Chronic Inflammatory Diseases, Anti-inflammatory +5

Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

Bruce E. Sands, Frank Anderson, Çharles N. Bernstein et al. · New England Journal of Medicine · 2004 · 2.2K citations · Full text

Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

Stephen B. Hanauer, William J. Sandborn, Paul Rutgeerts et al. · Gastroenterology · 2006 · 1.7K citations

Inflammation, Chronic Inflammatory Diseases, Autoimmune Disease +10

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

William J. Sandborn, Gert Van Assche, Walter Reinisch et al. · Gastroenterology · 2011 · 1.2K citations

Inflammation, Rheumatology, Autoimmune Disease +11

Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

William J. Sandborn, S. B. Hanauer, P. Rutgeerts et al. · Gut · 2007 · 1K citations · Full text